Gland Pharma Share Price
₹1,449.40 +6.8 (0.47%)
17 Apr, 2025 21:31
Start SIP in
GLAND
Performance
- Low
- ₹1,422
- High
- ₹1,455
- 52 Week Low
- ₹1,278
- 52 Week High
- ₹2,221
- Open Price₹1,455
- Previous Close₹1,443
- Volume140,459
Investment Returns
- Over 1 Month -6.78%
- Over 3 Month -13.51%
- Over 6 Month -13.02%
- Over 1 Year -17.17%
Smart Investing Starts Here Start SIP with Gland Pharma for Steady Growth!
Gland Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 33.9
- PEG Ratio
- 4.9
- Market Cap Cr
- 23,880
- P/B Ratio
- 2.7
- Average True Range
- 72.34
- EPS
- 42.75
- Dividend Yield
- 1.4
- MACD Signal
- -29.34
- RSI
- 40.25
- MFI
- 70.82
Gland Pharma Financials
Gland Pharma Technicals
EMA & SMA
-
- Bearish Moving Average 14
-
- Bullish Moving Average 2
- 20 Day
- ₹1,495.59
- 50 Day
- ₹1,546.13
- 100 Day
- ₹1,607.39
- 200 Day
- ₹1,675.53
Resistance and Support
- R3 1,494.80
- R2 1,474.80
- R1 1,462.10
- S1 1,429.40
- S2 1,409.40
- S3 1,396.70
Gland Pharma Corporate Actions - Bonus, Splits, Dividends
Gland Pharma F&O
About Gland Pharma
Gland Pharma is the leading company in creating some of the most beneficial injectable products that have significance in multiple therapeutic segments. In addition, the company is responsible for creating an online portfolio that allows users to buy their products online with a doctor's prescription. Right now, the company is manufacturing its products in seven different locations in India and which produce 750 million units with ease. The four major manufacturing facilities of the company have 22 production lines in order to provide finished formulations along with the Active Pharmaceutical Ingredient (API) Facilities as well. All the products that the company manufactures are delivered in the form of liquid vials, syringes that are pre-filled, ampoules, drops, and even bags as well.
In addition to this, the company is also putting a lot of effort into research for manufacturing and creating a delivery system that could hold complex injectables like peptides, suspensions, and long-lasting injectables. Apart from this, Gland Pharma Ltd is also putting its efforts into research and development of synthesizing some of the most complex molecules for the production of their injectables. Lastly, Gland Pharma Ltd is building the market of niche products in the pharmaceutical industry in India and throughout the world.
Products offered by Gland Pharma Ltd.
- Anti Malarials
- Anti-Infectives
- Anti-Neoplastics
- Blood Related
- Cardiac
- Gastro Intestinal
- Gynaecological
- Hormones
- Neuro / Cns
- Ophthal / Otologicals
- Others
- Pain / Analgesics
- Respiratory
- Vitamins / Minerals / Nutrients
Gland Pharma Ltd is listed on 2 exchanges, and these are:
- National Stock Exchange of India Ltd.
- The Stock Exchange, Mumbai
Included in Indices
- NIFTY 50 - No
- NIFTY next 50 - YES
- NIFTY 100 - YES
- S&P BSE 200 - YES
- S&P BSE 250 large midcap index- YES
- S&P BSE finance- NO
Other listing information
- Incorporation date - March 20 1978
- BSE group - A
- BSE Code - 543245
- NSE - GLANDEQ
1978
PVN Raju establishes Gland Pharma to manufacture and market Heparin injection in the domestic market, as well as to provide contract manufacturing services to other pharmaceutical companies.
1994
From a private limited company, it becomes a public limited company.
1996
Becomes the first company to establish a PFS facility in India.
2000
Signs its first Contract Manufacturing agreement for regulated markets
2007
Enters the US market with Ketorolac PFS
2013
Entered European markets with Tirofiban
The Visakhapatnam Oncology Formulations Facility has been approved by the USFDA.
2016
In 2016, the USFDA granted the first approval for a Penems plant in Hyderabad, as well as a Sterile Injectable plant in Pashamylaram, Hyderabad.
First USFDA approval for an API plant in VSEZ and another in Pharmacity, Visakhapatnam.
2017
Fosun Pharma acquired a majority stake in the company.
2018
Enoxaparin injection received US market approval in 2018.
The first ophthalmic product has been approved for sale in the United States.
- NSE Symbol
- GLAND
- BSE Symbol
- 543245
- Managing Director & CEO
- Mr. Srinivas Sadu
- ISIN
- INE068V01023
Similar Stocks to Gland Pharma
Gland Pharma FAQs
Gland Pharma share price is ₹1,449 As on 17 April, 2025 | 21:17
The Market Cap of Gland Pharma is ₹23879.8 Cr As on 17 April, 2025 | 21:17
The P/E ratio of Gland Pharma is 33.9 As on 17 April, 2025 | 21:17
The PB ratio of Gland Pharma is 2.7 As on 17 April, 2025 | 21:17
Gland Pharma has an operating revenue of Rs.3,981.54 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 39% is great. Various broking houses and analysts recommend 'BUY' on the stock.
The stock price CAGR of Gland Pharma Limited for 1 Year is 66%.
Gland Pharma Limited is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.
The ROE of Gland Pharma Limited is 16% is which good.
Mr. Srinivas Sadu is the Managing Director & Chief Executive Officer of Gland Pharma Limited.
The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.
Given below is the list of companies that belong to the same industry or manufacture products of a similar niche as Gland Pharma Ltd.
- Cipla
- Sun Pharma
- Pfizer
- Lupin
- Eris Life
- Aarti Drugs
- Hester Bio
- RPG Life
- Bafna Pharma
- Jb Chemicals
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.